---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-25-000090"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:40:43.769633+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biohaven reports Q3 net loss $173.4M, plans 60% R&D spend cut to focus on three late-stage programs

## Summary
- Net loss $173.4M ($1.64/share) vs $160.3M ($1.70/share) YoY; non-GAAP loss $155.9M ($1.47/share).
- R&D spend $141.2M, down 10% YoY; plans ~60% reduction in direct R&D spend going forward.
- Cash and equivalents $263.8M as of Sep 30, 2025.
- Restructuring: focus on opakalim (Kv7), extracellular degraders (BHV-1400/1300), and taldefgrobep (myostatin); other programs paused/halted.
- FDA Type A meeting requested to appeal CRL for SCA drug VYGLXIA; Phase 2 opakalim depression data expected Q4 2025.

## SEC filing metadata
- accession: 0001935979-25-000090
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000090/0001935979-25-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000090/bhvn-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-25-000090
- JSON: https://secwatch.observer/filing/0001935979-25-000090.json
- Plain text: https://secwatch.observer/filing/0001935979-25-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.